Citations

Showing 10 of 108094 citations.

Modern Surgical Treatment of Recurrent Posterior Dislocation of the Native Hip
Carlson, Bayard C. , Desy, Nicholas M. , Johnson, Joshua D. , Trousdale, Robert T. , Leunig, Michael , Ganz, Reinhold , Sierra, Rafael J. , Sierra, Rafael J

Mayo Clinic

Journal of Bone and Joint Surgery | June 20, 2018 | Volume: 100 | Issue: 12 | Pages: 1056-1063

10.2106/jbjs.17.01170 | PMID 29916934 Get It

Background: Redislocation of the native hip is rare. An anterior fulcrum between the proximal part of the femur and the pelvis must be present for a posterior dislocation to occur. The purpose of this study is to describe the cases of 9 patients with posterior redislocation or recurrent subluxation of the native hip that was treated with hip preservation surgery. Methods: We retrospectively identified the cases of 9 patients, from 2 institutions, who had undergone hip preservation surgery for the management of posterior redislocation or recurrent subluxation of the native hip after a dislocation. The mean number of dislocations prior to surgery was 3.2 (range, 1 to 7). Pelvic radiographs were used to classify the acetabular morphology, sufficiency of acetabular containment, and structural anatomy of the proximal part of the femur. Radiographic identification of impinging structures was used to guide surgical treatment, which involved either femoral correction alone or the combination of femoral correction and an anteverting periacetabular osteotomy. Results: At a mean follow-up of 73.8 months (range, 10 to 192 months), there had been no subsequent episodes of dislocation or subluxation in any of the hips treated with correction of the anatomic pivot point. An algorithmic approach is presented. Conclusions: In patients who have episodes of redislocation or recurrent subluxation of the native hip, the identification of anatomic abnormalities that create a fulcrum between the proximal part of the femur and the pelvis is critical for making appropriate treatment decisions. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Intravenous Versus Topical Tranexamic Acid in Total Knee Arthroplasty
Abdel, Matthew P. , Taunton, Michael J. , Pagnano, Mark W. , Trousdale, Robert T. , Lee, Yuo-yu, Su, Edwin P. , Haas, Steven B., Figgie, Mark P. , Mayman, David J. , Chalmers, Brian P. , Abdel, Matthew P , Taunton, Michael J , Sierra, Rafael J. , Lee, Yuo-yu , Boettner, Friedrich

Mayo Clinic

Journal of Bone and Joint Surgery | June 20, 2018 | Volume: 100 | Issue: 12 | Pages: 1023-1029

10.2106/jbjs.17.00908 | PMID 29916929 Get It

Background: Tranexamic acid (TXA) reduces bleeding and the need for transfusion after total knee arthroplasty. Most literature has focused on intravenous (IV) administration of TXA, with less data available on the efficacy of topically administered TXA. This multicenter randomized clinical trial specifically assessed the efficacy of topical TXA compared with IV TXA as measured by calculated blood loss, drain output, and transfusion rates. Complications, including venous thromboembolism (VTE), were reported. Methods: A total of 640 patients who underwent primary unilateral total knee arthroplasty for osteoarthritis at 2 large academic centers were randomized to receive 1 g of IV TXA prior to tourniquet inflation and 1 g at closure, or 3 g of TXA diluted in 45 mL of normal saline solution (total volume of 75 mL) and topically applied after cementation. Age, sex, body mass index, American Society of Anesthesiologists (ASA) score, and preoperative hemoglobin level were similar between the groups. Univariate, multiple linear regression, and multiple logistic regression analyses were performed. Results: Patients who received topical TXA had significantly greater calculated blood loss compared with those who received IV TXA (mean of 324 compared with 271 mL; p = 0.005). Drain output was significantly higher in the topical TXA group compared with the IV TXA group (mean of 560 compared with 456 mL; p < 0.0001). The rate of transfusion was low in the topical and IV groups, with no significant difference on univariate analysis (1.6% compared with 0.6%, respectively; p = 0.45); however, on multiple logistic regression analysis, patients who received topical TXA were 2.2-fold more likely to receive a transfusion (p < 0.0001). The topical and IV TXA groups did not differ significantly with respect to the rate of thrombotic events (0.6% compared with 1.6%, respectively; p = 0.45). Conclusions: In this large, randomized clinical trial involving patients undergoing total knee arthroplasty, both IV and topical TXA were associated with a low rate of transfusion. While IV TXA was associated with less calculated blood loss, lower drain output, and fewer transfusions, the small differences between the groups may not be clinically important. Given the low prevalence of thrombotic complications, the relative safety of one formulation of TXA over the other cannot be definitely established. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
A Systematic Overview of Zoonotic Helminth Infections in North America
Mathison, Blaine A. , Pritt, Bobbi S. , Pritt, Bobbi S , Mathison, Blaine A

Mayo Clinic

Laboratory Medicine | June 20, 2018 | Volume: 49 | Issue: 4 | Pages: e61-e93

10.1093/labmed/lmy029 | PMID 30032297 Get It

Predictive Value of Septal Flash for Reduction of Left Ventricular Systolic Function as Reflected by Global Longitudinal Strain Using Echocardiography in Patients With Isolated Complete Left Bundle-Branch Block
Wang, Yonghuai, Li, Guangyuan , Ma, Chunyan , Guan, Zhengyu, Jin, Xuanyi , Li, Yang , Yang, Jun , Wang, Yonghuai , Liu, Shuang

Mayo Clinic

Circulation Journal | June 20, 2018 | Volume: 82 | Issue: 8 | Pages: 2111-2118

10.1253/circj.cj-17-1422 | PMID 29925741 Get It

Letter to the Editor: “Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs”
Castillo-Castro, Carolina , Gonzalez‐Velazquez, Camilo , Rodríguez‐Gutiérrez, René , González-Velázquez, Camilo

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 20, 2018 | Volume: 103 | Issue: 9 | Pages: 3520-3520

10.1210/jc.2018-00884 | PMID 29931188 Get It

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
Chu, Edward , Allegra, Carmen J. , Tanigawara, Yusuke , Milano, G. , Diasio, Robert B. , Kim, Tae Won , Mathijssen, Ron H.J. , Muneoka, Katsuki, Diasio, Robert, Beumer, Jan Hendrik , Zhang, Li , Arnold, Dirk , Boku, Narikazu , Joerger, Markus

Mayo Clinic

Clinical Pharmacology & Therapeutics | June 20, 2018 | Volume: 105 | Issue: 3 | Pages: 598-613

10.1002/cpt.1124 | PMID 29923599 Get It

5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5‐FU therapy in patients with colorectal or head‐and‐neck cancer receiving common 5‐FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.
Effect of Open- vs Closed-Cell Stent Design on Periprocedural Outcomes and Restenosis After Carotid Artery Stenting: A Systematic Review and Comprehensive Meta-analysis
Texakalidis, Pavlos , Giannopoulos, Stefanos , Kokkinidis, Damianos G , Lanzino, Giuseppe

Mayo Clinic

Journal of Endovascular Therapy | June 20, 2018 | Volume: 25 | Issue: 4 | Pages: 523-533

10.1177/1526602818783505 | PMID 29923453 Get It

Purpose:To compare periprocedural complications and in-stent restenosis rates associated with open- vs closed-cell stent designs used in carotid artery stenting (CAS). Methods: A systematic search was conducted to identify all randomized and observational studies published in English up to October 31, 2017, that compared open- vs closed-cell stent designs in CAS. Identified studies were included if they reported the following outcomes: stroke, transient ischemic attack (TIA), myocardial infarction (MI), hemodynamic depression, new ischemic lesions detected on imaging, and death within 30 days, as well as the incidence of in-stent restenosis. A random-effects model meta-analysis was employed. Model results are reported as the odds ratio (OR) and 95% confidence interval (CI). The I 2 statistic was used to assess heterogeneity. Results: Thirty-three studies (2 randomized trials) comprising 20, 291 patients (mean age 71.3±3.0 years; 74.6% men) were included. Patients in the open-cell stent group had a statistically significant lower risk of restenosis ⩾40% (OR 0.42, 95% CI 0.19 to 0.92; I 2 =0%) and ⩾70% (OR 0.23, 95% CI 0.10 to 0.52; I 2 =0%) at a mean follow-up of 24 months. No statistically significant differences were identified for periprocedural stroke, TIA, new ischemic lesions, MI, hemodynamic depression, or death within 30 days after CAS. Sensitivity analysis of the 2 randomized controlled trials only did not point to any significant differences either. Conclusion: Use of open-cell stent design in CAS is associated with a decreased risk for restenosis when compared to the closed-cell stent, without significant differences in periprocedural outcomes.
Expression of the ectodomain‐releasing protease ADAM17 is directly regulated by the osteosarcoma and bone‐related transcription factor RUNX2
Araya, Héctor, Sepúlveda, Hugo , Lizama, Carlos O. , Vega, Oscar A., Jerez, Sofía , Briceño, Pedro, Thaler, Roman, Riester, Scott M. , Antonelli, Marcelo , Salazar‐Onfray, Flavio , Montecino, Martı́n , Charbonneau, Martine , Dubois, Claire M. , Stein, Gary S., Wijnen, André J. van , Galindo, Mario , van Wijnen, Andre J , Galindo, Mario A , Rodríguez, Juan Pablo , Moreno, Ricardo D. , Dubois, Claire M

Mayo Clinic

Journal of Cellular Biochemistry | June 20, 2018 | Volume: 119 | Issue: 10 | Pages: 8204-8219

10.1002/jcb.26832 | PMID 29923217 Get It

AbstractOsteoblast differentiation is controlled by transcription factor RUNX2 which temporally activates or represses several bone‐related genes, including those encoding extracellular matrix proteins or factors that control cell‐cell, and cell‐matrix interactions. Cell‐cell communication in the many skeletal pericellular micro‐niches is critical for bone development and involves paracrine secretion of growth factors and morphogens. This paracrine signaling is in part regulated by “A Disintegrin And Metalloproteinase” (ADAM) proteins. These cell membrane‐associated metalloproteinases support proteolytic release (“shedding”) of protein ectodomains residing at the cell surface. We analyzed microarray and RNA‐sequencing data for Adam genes and show that Adam17, Adam10, and Adam9 are stimulated during BMP2 mediated induction of osteogenic differentiation and are robustly expressed in human osteoblastic cells. ADAM17, which was initially identified as a tumor necrosis factor alpha (TNFα) converting enzyme also called (TACE), regulates TNFα‐signaling pathway, which inhibits osteoblast differentiation. We demonstrate that Adam17 expression is suppressed by RUNX2 during osteoblast differentiation through the proximal Adam17 promoter region (−0.4 kb) containing two functional RUNX2 binding motifs. Adam17 downregulation during osteoblast differentiation is paralleled by increased RUNX2 expression, cytoplasmic‐nuclear translocation and enhanced binding to the Adam17 proximal promoter. Forced expression of Adam17 reduces Runx2 and Alpl expression, indicating that Adam17 may negatively modulate osteoblast differentiation. These findings suggest a novel regulatory mechanism involving a reciprocal Runx2‐Adam17 negative feedback loop to regulate progression through osteoblast differentiation. Our results suggest that RUNX2 may control paracrine signaling through regulation of ectodomain shedding at the cell surface of osteoblasts by directly suppressing Adam17 expression.
Role of Bisphosphonates in Vascular calcification and Bone Metabolism: A Clinical Summary
Dayanand, Pradeep, Dayanand, Sandeep , Martinez, J., Rangaswami, Janani , Sandhyavenu, Harigopal

Mayo Clinic

Current Cardiology Reviews | June 20, 2018 | Volume: 14 | Issue: 3 | Pages: 192-199

10.2174/1573403x14666180619103258 | PMID 29921207 Get It

Ethylene glycol and methanol ingestion cared for by tele-emergency pharmacy and tele-emergency medicine
Russi, Christopher S. , Mattson, Alicia E , Smars, Peter A., Newman, James S. , Beuning, Alex J

Mayo Clinic

Journal of Telemedicine and Telecare | June 20, 2018 | Volume: 25 | Issue: 7 | Pages: 445-447

10.1177/1357633x18778631 | PMID 29921165 Get It

We believe this is the first documented case of a critically ill patient managed by telepharmacy in a remote, rural critical access hospital. We outline the case and the benefits of telepharmacy in under-resourced, rural critical access emergency departments.